Latest news with #AustralianShares
Yahoo
06-07-2025
- Business
- Yahoo
ASX Penny Stocks Spotlight: Emerald Resources And Two More To Consider
As Australian shares aim for a modest rise, the market remains influenced by global events, including record highs in U.S. indices and geopolitical tensions. Amidst these broader market dynamics, penny stocks continue to capture investor interest due to their potential for growth at relatively low price points. While the term "penny stocks" might seem outdated, these investments often involve smaller or newer companies that can offer significant upside when backed by strong financial fundamentals. Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.365 A$104.6M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.29 A$108.03M ★★★★★★ GTN (ASX:GTN) A$0.62 A$118.24M ★★★★★★ IVE Group (ASX:IGL) A$2.86 A$440.96M ★★★★★☆ Duratec (ASX:DUR) A$1.435 A$362.18M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.785 A$471.97M ★★★★★★ Sugar Terminals (NSX:SUG) A$0.99 A$363.6M ★★★★★★ Navigator Global Investments (ASX:NGI) A$1.77 A$867.44M ★★★★★☆ Bisalloy Steel Group (ASX:BIS) A$4.15 A$196.92M ★★★★★★ CTI Logistics (ASX:CLX) A$1.80 A$144.98M ★★★★☆☆ Click here to see the full list of 468 stocks from our ASX Penny Stocks screener. Let's uncover some gems from our specialized screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Emerald Resources NL focuses on the exploration and development of mineral reserves in Cambodia and Australia, with a market cap of A$2.60 billion. Operations: The company generates revenue primarily from its Mine Operations segment, which accounts for A$427.32 million. Market Cap: A$2.6B Emerald Resources has demonstrated significant financial strength and growth, with its earnings increasing by 32.2% over the past year, surpassing industry averages. The company maintains a solid balance sheet, as its debt is well covered by operating cash flow and it holds more cash than total debt. Recent production guidance indicates robust gold output from the Okvau Gold Mine through 2026, suggesting operational stability. Despite a low Return on Equity of 15.6%, Emerald's net profit margins have improved to 23.2%, reflecting efficient management practices without shareholder dilution in the past year. Unlock comprehensive insights into our analysis of Emerald Resources stock in this financial health report. Explore Emerald Resources' analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: RPMGlobal Holdings Limited develops and provides mining software solutions across Australia, Asia, the Americas, Africa, and Europe with a market cap of A$717.37 million. Operations: RPMGlobal Holdings generates revenue primarily from its Software segment, which accounts for A$74.88 million, and its Advisory services, contributing A$34.17 million. Market Cap: A$717.37M RPMGlobal Holdings has shown financial resilience with no debt over the past five years, supported by experienced management and board members. Despite a stable weekly volatility of 7%, RPMGlobal faces challenges with declining earnings, forecasted to decrease by an average of 27.2% annually over the next three years. The company's net profit margin has dropped from 9.7% last year to 6.2%, and its Return on Equity is considered low at 12%. However, RPMGlobal's short-term assets comfortably cover both short-term and long-term liabilities, ensuring a solid liquidity position amidst these challenges. Take a closer look at RPMGlobal Holdings' potential here in our financial health report. Evaluate RPMGlobal Holdings' prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Web Travel Group Limited offers online travel booking services across Australia, the United Arab Emirates, the United Kingdom, and internationally, with a market cap of A$1.61 billion. Operations: The company generates revenue from its Business to Business Travel (B2B) segment, amounting to A$328.4 million. Market Cap: A$1.61B Web Travel Group's financial profile reveals a mixed picture for potential investors. While the company boasts a substantial market cap of A$1.61 billion and generates significant revenue from its B2B segment, recent earnings growth has been negative at -85.9%, with profit margins dropping to 3.4% from 24.6% last year, partly due to large one-off losses impacting results. Despite these challenges, the company's short-term assets exceed both short-term and long-term liabilities, providing financial stability. Upcoming board changes may bring fresh perspectives as Melanie Wilson and Paul Scurrah join as independent non-executive directors in July 2025. Get an in-depth perspective on Web Travel Group's performance by reading our balance sheet health report here. Gain insights into Web Travel Group's future direction by reviewing our growth report. Take a closer look at our ASX Penny Stocks list of 468 companies by clicking here. Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:EMR ASX:RUL and ASX:WEB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
04-07-2025
- Business
- Yahoo
3 ASX Penny Stocks With Market Caps Over A$70M
As Australian shares anticipate a modest rise, the market is buzzing with activity, influenced by global indices like the S&P 500 reaching new heights. Amidst this backdrop, penny stocks continue to capture investor interest for their potential growth opportunities at accessible price points. While the term "penny stocks" might seem outdated, these smaller or newer companies can offer significant value when they possess strong financials and clear growth paths. Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.37 A$106.04M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.23 A$105.2M ★★★★★★ GTN (ASX:GTN) A$0.62 A$118.24M ★★★★★★ IVE Group (ASX:IGL) A$2.82 A$434.79M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.80 A$475.94M ★★★★★★ Sugar Terminals (NSX:SUG) A$0.99 A$363.6M ★★★★★★ Navigator Global Investments (ASX:NGI) A$1.71 A$838.04M ★★★★★☆ Accent Group (ASX:AX1) A$1.41 A$847.67M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.75 A$177.94M ★★★★★★ CTI Logistics (ASX:CLX) A$1.80 A$144.98M ★★★★☆☆ Click here to see the full list of 474 stocks from our ASX Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Amcil Limited is a publicly owned investment manager with a market cap of A$358.12 million. Operations: The company generates its revenue primarily from investments, amounting to A$9.74 million. Market Cap: A$358.12M Amcil Limited, with a market cap of A$358.12 million, primarily generates its revenue from investments totaling A$9.74 million. Despite negative earnings growth of -7.5% over the past year, Amcil's short-term assets (A$12.3M) comfortably exceed its short-term liabilities (A$2.9M). The company is debt-free and benefits from a seasoned management team with an average tenure of 9 years and an experienced board averaging 8.1 years in tenure. However, its dividend yield of 3.52% is not well covered by earnings or free cash flows, and long-term liabilities (A$49.8M) surpass short-term assets. Jump into the full analysis health report here for a deeper understanding of AMCIL. Assess AMCIL's previous results with our detailed historical performance reports. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Accent Group Limited operates in the retail, distribution, and franchise sectors for lifestyle footwear, apparel, and accessories across Australia and New Zealand, with a market cap of A$847.67 million. Operations: Accent Group generates its revenue primarily from two segments: Retail, which accounts for A$1.30 billion, and Wholesale, contributing A$475.92 million. Market Cap: A$847.67M Accent Group Limited, with a market cap of A$847.67 million, operates in the retail sector with substantial revenue streams from its Retail (A$1.30 billion) and Wholesale (A$475.92 million) segments. Despite recent negative earnings growth, the company is trading at a significant discount to its estimated fair value and offers high-quality earnings with well-covered interest payments on debt. Recent strategic initiatives include a partnership with Frasers Group to launch Sports Direct in Australasia, providing access to global brands and potential expansion opportunities. However, challenges include increased debt levels and lower net profit margins compared to last year. Navigate through the intricacies of Accent Group with our comprehensive balance sheet health report here. Assess Accent Group's future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: ImpediMed Limited is a medical technology company that manufactures and sells bioimpedance spectroscopy (BIS) technology medical devices in the United States and Europe, with a market cap of A$79.00 million. Operations: The company generates revenue of A$11.54 million from its medical segment. Market Cap: A$79M ImpediMed Limited, with a market cap of A$79 million, operates in the medical technology sector and generates A$11.54 million in revenue from its medical devices. The company is debt-free and has seen a reduction in losses over the past five years, although it remains unprofitable with no forecasted profitability within three years. Analysts expect significant stock price appreciation despite high volatility and limited cash runway under current conditions. The board and management are relatively new, indicating potential strategic shifts but also posing risks due to their lack of experience. Recent participation at an industry conference highlights ongoing engagement with key stakeholders. Click here and access our complete financial health analysis report to understand the dynamics of ImpediMed. Examine ImpediMed's earnings growth report to understand how analysts expect it to perform. Click this link to deep-dive into the 474 companies within our ASX Penny Stocks screener. Want To Explore Some Alternatives? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:AMH ASX:AX1 and ASX:IPD. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-07-2025
- Business
- Yahoo
3 ASX Penny Stocks With Market Caps Over A$70M
As Australian shares anticipate a modest rise, the market is buzzing with activity, influenced by global indices like the S&P 500 reaching new heights. Amidst this backdrop, penny stocks continue to capture investor interest for their potential growth opportunities at accessible price points. While the term "penny stocks" might seem outdated, these smaller or newer companies can offer significant value when they possess strong financials and clear growth paths. Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.37 A$106.04M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.23 A$105.2M ★★★★★★ GTN (ASX:GTN) A$0.62 A$118.24M ★★★★★★ IVE Group (ASX:IGL) A$2.82 A$434.79M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.80 A$475.94M ★★★★★★ Sugar Terminals (NSX:SUG) A$0.99 A$363.6M ★★★★★★ Navigator Global Investments (ASX:NGI) A$1.71 A$838.04M ★★★★★☆ Accent Group (ASX:AX1) A$1.41 A$847.67M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.75 A$177.94M ★★★★★★ CTI Logistics (ASX:CLX) A$1.80 A$144.98M ★★★★☆☆ Click here to see the full list of 474 stocks from our ASX Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Amcil Limited is a publicly owned investment manager with a market cap of A$358.12 million. Operations: The company generates its revenue primarily from investments, amounting to A$9.74 million. Market Cap: A$358.12M Amcil Limited, with a market cap of A$358.12 million, primarily generates its revenue from investments totaling A$9.74 million. Despite negative earnings growth of -7.5% over the past year, Amcil's short-term assets (A$12.3M) comfortably exceed its short-term liabilities (A$2.9M). The company is debt-free and benefits from a seasoned management team with an average tenure of 9 years and an experienced board averaging 8.1 years in tenure. However, its dividend yield of 3.52% is not well covered by earnings or free cash flows, and long-term liabilities (A$49.8M) surpass short-term assets. Jump into the full analysis health report here for a deeper understanding of AMCIL. Assess AMCIL's previous results with our detailed historical performance reports. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Accent Group Limited operates in the retail, distribution, and franchise sectors for lifestyle footwear, apparel, and accessories across Australia and New Zealand, with a market cap of A$847.67 million. Operations: Accent Group generates its revenue primarily from two segments: Retail, which accounts for A$1.30 billion, and Wholesale, contributing A$475.92 million. Market Cap: A$847.67M Accent Group Limited, with a market cap of A$847.67 million, operates in the retail sector with substantial revenue streams from its Retail (A$1.30 billion) and Wholesale (A$475.92 million) segments. Despite recent negative earnings growth, the company is trading at a significant discount to its estimated fair value and offers high-quality earnings with well-covered interest payments on debt. Recent strategic initiatives include a partnership with Frasers Group to launch Sports Direct in Australasia, providing access to global brands and potential expansion opportunities. However, challenges include increased debt levels and lower net profit margins compared to last year. Navigate through the intricacies of Accent Group with our comprehensive balance sheet health report here. Assess Accent Group's future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: ImpediMed Limited is a medical technology company that manufactures and sells bioimpedance spectroscopy (BIS) technology medical devices in the United States and Europe, with a market cap of A$79.00 million. Operations: The company generates revenue of A$11.54 million from its medical segment. Market Cap: A$79M ImpediMed Limited, with a market cap of A$79 million, operates in the medical technology sector and generates A$11.54 million in revenue from its medical devices. The company is debt-free and has seen a reduction in losses over the past five years, although it remains unprofitable with no forecasted profitability within three years. Analysts expect significant stock price appreciation despite high volatility and limited cash runway under current conditions. The board and management are relatively new, indicating potential strategic shifts but also posing risks due to their lack of experience. Recent participation at an industry conference highlights ongoing engagement with key stakeholders. Click here and access our complete financial health analysis report to understand the dynamics of ImpediMed. Examine ImpediMed's earnings growth report to understand how analysts expect it to perform. Click this link to deep-dive into the 474 companies within our ASX Penny Stocks screener. Want To Explore Some Alternatives? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:AMH ASX:AX1 and ASX:IPD. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
17-06-2025
- Business
- Yahoo
ASX Penny Stocks Uncovered: Judo Capital Holdings Among 3 Promising Picks
As Australian shares are expected to edge up slightly, recovering from earlier losses, investors are keenly observing the broader market dynamics influenced by geopolitical developments and commodity price fluctuations. Despite their vintage name, penny stocks continue to offer intriguing opportunities for those interested in smaller or newer companies. With strong financial foundations, these stocks can potentially provide significant returns; this article will explore three such promising examples on the ASX. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$2.02 A$95.29M ★★★★★★ GTN (ASX:GTN) A$0.62 A$118.33M ★★★★★★ IVE Group (ASX:IGL) A$2.71 A$417.83M ★★★★★☆ GR Engineering Services (ASX:GNG) A$2.97 A$497.04M ★★★★★★ West African Resources (ASX:WAF) A$2.30 A$2.62B ★★★★★★ Southern Cross Electrical Engineering (ASX:SXE) A$1.65 A$436.28M ★★★★★★ Tasmea (ASX:TEA) A$3.12 A$735.14M ★★★★★☆ Lindsay Australia (ASX:LAU) A$0.70 A$222.02M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.15 A$149.47M ★★★★★★ CTI Logistics (ASX:CLX) A$1.76 A$141.76M ★★★★☆☆ Click here to see the full list of 1,006 stocks from our ASX Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Judo Capital Holdings Limited operates through its subsidiaries to provide a range of banking products and services tailored for small and medium businesses in Australia, with a market capitalization of A$1.75 billion. Operations: The company generates revenue of A$325.5 million from its banking operations focused on small and medium enterprises in Australia. Market Cap: A$1.75B Judo Capital Holdings Limited, with a market capitalization of A$1.75 billion, focuses on small and medium enterprises in Australia, generating A$325.5 million in revenue from its banking operations. Despite recent negative earnings growth (-22%), the company maintains high-quality past earnings and has not diluted shareholders over the past year. Its Loans to Deposits ratio is high at 128%, but it manages an appropriate level of bad loans (1.2%) with sufficient allowance (111%). The management team and board are experienced, with average tenures of 3.3 and 4.6 years respectively, providing stability amidst market volatility. Jump into the full analysis health report here for a deeper understanding of Judo Capital Holdings. Assess Judo Capital Holdings' future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Kairos Minerals Limited, with a market cap of A$81.56 million, is an Australian resource exploration company operating through its subsidiaries. Operations: Kairos Minerals Limited has not reported any specific revenue segments. Market Cap: A$81.56M Kairos Minerals Limited, with a market cap of A$81.56 million, is pre-revenue and unprofitable but has reduced its losses by 24.9% annually over the past five years. The company is debt-free and boasts short-term assets of A$12.7 million that comfortably cover both short-term (A$312.6K) and long-term liabilities (A$42.2K). It possesses a cash runway exceeding three years based on current free cash flow levels, providing financial stability amidst high weekly volatility of 13%. Both its board and management team are experienced, with average tenures of 3.1 years each, ensuring seasoned oversight during this growth phase. Take a closer look at Kairos Minerals' potential here in our financial health report. Understand Kairos Minerals' track record by examining our performance history report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Renascor Resources Limited focuses on the exploration, development, and evaluation of mineral properties in Australia, with a market capitalization of A$172.93 million. Operations: The company's revenue segment includes exploration activities for graphite, copper, gold, uranium, and other minerals, generating A$0.075 million. Market Cap: A$172.93M Renascor Resources Limited, with a market cap of A$172.93 million, is pre-revenue, generating only A$0.075 million from exploration activities. Despite its high share price volatility and low return on equity (1%), the company maintains financial stability with short-term assets of A$109.8 million exceeding both short-term (A$3.4 million) and long-term liabilities (A$27.9K). The company benefits from being debt-free for the past five years and has an experienced board averaging 14.7 years in tenure, providing strong governance as it progresses its Battery Anode Material project updates and engages in industry conferences. Get an in-depth perspective on Renascor Resources' performance by reading our balance sheet health report here. Assess Renascor Resources' previous results with our detailed historical performance reports. Jump into our full catalog of 1,006 ASX Penny Stocks here. Searching for a Fresh Perspective? We've found 20 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:JDO ASX:KAI and ASX:RNU. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
16-06-2025
- Business
- Yahoo
GR Engineering Services And 2 Other ASX Penny Stocks To Consider
As Australian shares brace for a potential dip amid geopolitical tensions and economic updates from China, investors are keenly observing market movements. In such uncertain times, identifying stocks with solid financials and growth potential becomes crucial. Penny stocks, though an old term, continue to offer intriguing opportunities in the realm of smaller or newer companies; when backed by robust fundamentals, these investments can provide both stability and upside potential. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.775 A$83.73M ★★★★★★ GTN (ASX:GTN) A$0.62 A$118.33M ★★★★★★ IVE Group (ASX:IGL) A$2.70 A$416.29M ★★★★★☆ West African Resources (ASX:WAF) A$2.36 A$2.69B ★★★★★★ Southern Cross Electrical Engineering (ASX:SXE) A$1.65 A$436.28M ★★★★★★ Tasmea (ASX:TEA) A$3.11 A$732.78M ★★★★★☆ Regal Partners (ASX:RPL) A$2.11 A$709.31M ★★★★★★ Lindsay Australia (ASX:LAU) A$0.72 A$228.36M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.22 A$152.79M ★★★★★★ CTI Logistics (ASX:CLX) A$1.76 A$141.76M ★★★★☆☆ Click here to see the full list of 1,005 stocks from our ASX Penny Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: GR Engineering Services Limited offers engineering, procurement, and construction services to the mining and mineral processing sectors both in Australia and globally, with a market cap of A$512.10 million. Operations: The company generates revenue from two main segments: Oil and Gas, contributing A$96.61 million, and Mineral Processing, which accounts for A$412.30 million. Market Cap: A$512.1M GR Engineering Services Limited, with a market cap of A$512.10 million, is financially robust, boasting no debt and outstanding Return on Equity at 53%. It has experienced consistent earnings growth over the past five years, recently accelerating to 34.3% in the last year alone. The company's short-term assets exceed both its short-term and long-term liabilities, indicating strong liquidity. Despite an unstable dividend track record, GR Engineering's high-quality earnings and stable volatility make it a compelling option for investors interested in penny stocks. Recently, it secured a contract with Horizon Minerals for engineering studies on the Black Swan processing plant refurbishment. Take a closer look at GR Engineering Services' potential here in our financial health report. Examine GR Engineering Services' past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Optiscan Imaging Limited develops, manufactures, and commercializes endomicroscopic digital imaging technology for medical and pre-clinical applications across Australia, Germany, China, and the United States with a market cap of A$104.42 million. Operations: The company generates revenue from its Confocal Microscopes segment, amounting to A$4.96 million. Market Cap: A$104.42M Optiscan Imaging Limited, with a market cap of A$104.42 million, is navigating financial challenges as it remains unprofitable and lacks meaningful revenue. However, the company benefits from a strong cash position that covers both short-term liabilities (A$1.4M) and long-term liabilities (A$13.9K), alongside having more cash than debt. Recent executive changes aim to enhance its strategic focus on clinical and regulatory strategies for product development across key markets like the US MedTech sector. Despite high share price volatility, Optiscan's experienced board provides stability as it seeks to capitalize on its expanding product portfolio. Jump into the full analysis health report here for a deeper understanding of Optiscan Imaging. Review our historical performance report to gain insights into Optiscan Imaging's track record. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Tyranna Resources Limited is engaged in the exploration and development of mineral properties both in Australia and internationally, with a market cap of A$19.73 million. Operations: The company generates revenue from its exploration activities in Angola, amounting to A$0.08 million. Market Cap: A$19.73M Tyranna Resources Limited, with a market cap of A$19.73 million, is pre-revenue and unprofitable, generating minimal revenue from exploration activities in Angola. The company has a seasoned management team but an inexperienced board with an average tenure of 2.8 years. Despite being debt-free and having short-term assets (A$4.8M) exceeding liabilities (A$94.9K), Tyranna faces financial challenges with less than a year of cash runway if current cash flow trends continue to decline by 13.3% annually. Its share price remains highly volatile, reflecting investor uncertainty amidst increasing losses over the past five years at 61% per year. Click here to discover the nuances of Tyranna Resources with our detailed analytical financial health report. Gain insights into Tyranna Resources' past trends and performance with our report on the company's historical track record. Discover the full array of 1,005 ASX Penny Stocks right here. Contemplating Other Strategies? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:GNG ASX:OIL and ASX:TYX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
